Juan Carlos
Vallejo Llamas
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (1)
2017
-
Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in spain
ClinicoEconomics and Outcomes Research, Vol. 9, pp. 39-47